Literature DB >> 25937189

Adversomics: a new paradigm for vaccine safety and design.

Jennifer A Whitaker1, Inna G Ovsyannikova, Gregory A Poland.   

Abstract

Despite the enormous population benefits of routine vaccination, vaccine adverse events (AEs) and reactions, whether real or perceived, have posed one of the greatest barriers to vaccine acceptance--and thus to infectious disease prevention--worldwide. A truly integrated clinical, translational, and basic science approach is required to understand the mechanisms behind vaccine AEs, predict them, and then apply this knowledge to new vaccine design approaches that decrease, or avoid, these events. The term 'adversomics' was first introduced in 2009 and refers to the study of vaccine adverse reactions using immunogenomics and systems biology approaches. In this review, we present the current state of adversomics research, review known associations and mechanisms of vaccine AEs/reactions, and outline a plan for the further development of this emerging research field.

Entities:  

Keywords:  drug-related side effects and adverse reactions; genetic association studies; genomics; immunogenetics; individualized medicine; polymorphism; single nucleotide; systems biology; vaccination; vaccines; viral vaccines

Mesh:

Substances:

Year:  2015        PMID: 25937189      PMCID: PMC4630804          DOI: 10.1586/14760584.2015.1038249

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  117 in total

1.  Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2013-06-24       Impact factor: 2.850

Review 2.  Public fear of vaccination: separating fact from fiction.

Authors:  Ian Amanna; Mark K Slifka
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

3.  Concurrent HLA-related response factors mediate recombinant hepatitis B vaccine major adverse events.

Authors:  J D Miller; L H Whitehair
Journal:  Autoimmunity       Date:  2005-03       Impact factor: 2.815

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

Authors:  X Q Chen; M Bülbül; G C de Gast; A M van Loon; D R Nalin; J van Hattum
Journal:  J Hepatol       Date:  1997-02       Impact factor: 25.083

6.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

7.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

8.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

9.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

Authors:  Diana Chessman; Lyudmila Kostenko; Tessa Lethborg; Anthony W Purcell; Nicholas A Williamson; Zhenjun Chen; Lars Kjer-Nielsen; Nicole A Mifsud; Brian D Tait; Rhonda Holdsworth; Coral Ann Almeida; David Nolan; Whitney A Macdonald; Julia K Archbold; Anthony D Kellerher; Debbie Marriott; Simon Mallal; Mandvi Bharadwaj; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

10.  Gender effects on humoral immune responses to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Margaret A K Ryan; Gregory A Poland
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

View more
  22 in total

1.  Early molecular correlates of adverse events following yellow fever vaccination.

Authors:  Candice Yy Chan; Kuan Rong Chan; Camillus Jh Chua; Sharifah Nur Hazirah; Sujoy Ghosh; Eng Eong Ooi; Jenny G Low
Journal:  JCI Insight       Date:  2017-10-05

2.  Authors' reply: Safety of Human Papillomavirus Vaccines.

Authors:  Kristine Macartney; Anastasia Phillips; Cyra Patel; Alexis Pillsbury; Julia Brotherton
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

3.  Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI).

Authors: 
Journal:  J Prev Med Hyg       Date:  2019-10-15

4.  Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.

Authors:  Eli Magen; Avi Yakov; Ilan Green; Ariel Israel; Shlomo Vinker; Eugene Merzon
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

5.  COVID-19 Pandemic-Revealed Consistencies and Inconsistencies in Healthcare: A Medical and Organizational View.

Authors:  Diana Araja; Uldis Berkis; Modra Murovska
Journal:  Healthcare (Basel)       Date:  2022-05-31

6.  The International Society of Pharmacovigilance Vaccines Special Interest Group: Challenges and Opportunities.

Authors:  Rebecca E Chandler
Journal:  Drug Saf       Date:  2022-05-09       Impact factor: 5.228

7.  Ethically utilising COVID-19 host-genomic data.

Authors:  Christopher Gyngell; John Christodoulou; Julian Savulescu
Journal:  NPJ Genom Med       Date:  2021-05-10       Impact factor: 8.617

Review 8.  Vaccinology in the third millennium: scientific and social challenges.

Authors:  Gregory A Poland; Jennifer A Whitaker; Caroline M Poland; Inna G Ovsyannikova; Richard B Kennedy
Journal:  Curr Opin Virol       Date:  2016-03-30       Impact factor: 7.090

Review 9.  Personalized vaccinology: A review.

Authors:  G A Poland; I G Ovsyannikova; R B Kennedy
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 4.169

Review 10.  Vaccines Meet Big Data: State-of-the-Art and Future Prospects. From the Classical 3Is ("Isolate-Inactivate-Inject") Vaccinology 1.0 to Vaccinology 3.0, Vaccinomics, and Beyond: A Historical Overview.

Authors:  Nicola Luigi Bragazzi; Vincenza Gianfredi; Milena Villarini; Roberto Rosselli; Ahmed Nasr; Amr Hussein; Mariano Martini; Masoud Behzadifar
Journal:  Front Public Health       Date:  2018-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.